IBM
IBM
$212.67
-2.91%
International Business Machines (IBM) is a global technology company that provides software, IT consulting services, and hardware to help businesses modernize their workflows, operating in 175 countries. As a legacy tech giant with a robust partner ecosystem serving 95% of Fortune 500 companies, IBM distinguishes itself through its hybrid cloud and AI platform, including Red Hat and watsonx. The current investor narrative is dominated by a dramatic profit warning and a 25% stock plunge triggered by a shift in enterprise spending from software to hardware, raising concerns about near-term growth and the pace of AI monetization.…
IBM
IBM
$212.67
Related headlines
Investment Opinion: Should I buy IBM Today?
Rating: Hold. IBM is a classic value trap scenario — cheap on forward earnings (15.87x P/E) but facing a severe cyclical downturn that could persist. The analyst consensus is Buy with an average target of $296.07, implying 40% upside, but the recent profit warning and 25% crash demand caution. The core thesis is that the stock's low valuation and strong cash flow provide a floor, but the near-term earnings trajectory is highly uncertain.
Supporting Evidence: The forward P/E of 15.87x is below the industry average of ~20-22x, and the PEG ratio of 0.35 suggests undervaluation relative to expected growth. Revenue grew 9.5% YoY in Q1 2026, but the profit warning indicates a sharp deceleration. Gross margin remains healthy at 59.5%, and TTM free cash flow of $14.58 billion covers the dividend comfortably. However, the trailing P/E of 26.07x is a premium, and the net loss in Q2 2026 undermines earnings quality. The implied upside to the average analyst target is 40.2%, but the wide range ($195-$390) reflects low conviction.
Risks & Conditions: The biggest risks are (1) the profit warning being the start of a prolonged downturn, (2) further analyst downgrades, and (3) a break below the 52-week low of $211.03. This Hold would upgrade to Buy if the stock stabilizes above $220 and Q3 earnings show a recovery in software revenue. It would downgrade to Sell if the stock breaks below $195 or if free cash flow deteriorates significantly. Overall, IBM appears fairly valued on a forward basis but overvalued on trailing earnings, making it a speculative hold for patient investors willing to weather near-term volatility.
Sign up to view all
IBM 12-Month Price Forecast
The AI assessment is bearish with high confidence. IBM's severe underperformance, the profit warning, and the stock's proximity to its 52-week low indicate a high probability of further downside. The forward P/E of 15.87x is attractive, but it relies on earnings estimates that are likely to be revised downward. The key factor to watch is whether the spending shift is temporary or structural. If Q3 earnings show stabilization, the stance could upgrade to neutral; if they disappoint, a break below $211 could trigger a sell-off toward $195.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IBM's 12-month outlook, with a consensus price target around $283.80 and implied upside of +33.5% versus the current price.
Average Target
$283.80
0 analysts
Implied Upside
+33.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $375
Analyst target range
IBM is covered by 23 analysts, with a consensus recommendation of 'Buy' (mean rating 1.96 on a 1-5 scale where 1 is Strong Buy). The average target price is $296.07, implying 40.2% upside from the current price of $211.20. The distribution shows a bullish tilt, with recent actions including upgrades from JP Morgan (Neutral to Overweight) and reaffirmations from BofA (Buy) and Wedbush (Outperform). However, HSBC downgraded to Reduce, and the profit warning has likely increased uncertainty.
The target range spans from $195.00 (low) to $390.00 (high), a spread of $195, indicating high uncertainty. The high target of $390 implies a P/E of ~30x on forward estimates, assuming a return to growth and multiple expansion. The low target of $195 suggests a scenario where earnings disappoint further, potentially due to prolonged spending shifts or margin erosion. Recent analyst actions show a mix: JP Morgan upgraded, but HSBC downgraded, reflecting divergent views. The wide spread and mixed revisions suggest low conviction, and investors should be cautious about relying on the average target. The implied 40% upside is attractive but contingent on a successful turnaround.
Drowning in data?
Find the real signal!
Bulls vs Bears: IBM Investment Factors
IBM presents a deeply conflicted investment case. On the bull side, the stock offers a compelling forward valuation (15.87x P/E), strong free cash flow ($14.58B TTM), and a consensus analyst target implying 40% upside. On the bear side, the recent profit warning and 25% crash reflect a structural shift in enterprise spending away from software, IBM's core strength, and the stock is in a severe downtrend near its 52-week low. The single most important tension is whether the profit warning is a temporary cyclical blip or the start of a secular decline in IBM's software business. If the spending shift reverses or IBM successfully adapts, the stock could rebound sharply; if not, further downside toward the $195 low analyst target is likely. Currently, the bearish evidence from the price action and earnings deterioration outweighs the bullish valuation case, making this a high-risk, high-reward situation.
Bullish
- Strong free cash flow generation: IBM generated $14.58 billion in TTM free cash flow, providing ample capacity for dividends and debt reduction. This cash flow strength supports a 2.27% dividend yield with a 59% payout ratio, offering a margin of safety.
- Attractive forward valuation: The forward P/E of 15.87x is near the lower end of its historical range and below the industry average of ~20-22x. The PEG ratio of 0.35 suggests the stock is cheap relative to expected earnings growth, assuming a recovery.
- Analyst consensus bullish with 40% upside: 23 analysts rate IBM a Buy with an average target of $296.07, implying 40.2% upside from $211.20. Recent upgrades from JP Morgan and BofA indicate some confidence in a turnaround.
- High gross margins and ROE: Gross margin of 59.5% and ROE of 32.4% demonstrate strong profitability and efficient use of equity. These metrics are competitive within the IT services sector and support long-term value creation.
Bearish
- Profit warning triggered 25% stock crash: On July 14, IBM issued a profit warning as enterprise spending shifted from software to hardware, causing a 25% single-day drop. Q2 2026 net income swung to a loss of $1.22 billion from a profit of $2.19 billion a year earlier, signaling severe earnings deterioration.
- Stock in freefall, near 52-week low: IBM is trading at $211.20, just 0.1% above its 52-week low of $211.03 and 36.5% below its high of $332.46. The 1-month decline of 21.4% and 1-year decline of 25.3% versus the S&P 500's 20.9% gain indicate extreme underperformance and negative momentum.
- Valuation premium on trailing earnings: The trailing P/E of 26.07x is above the industry average of ~20-22x, and the price-to-sales ratio of 4.09x is also elevated. This premium is hard to justify given the recent earnings miss and uncertain growth outlook.
- High debt and low liquidity: Debt-to-equity of 2.06 and current ratio of 0.93 indicate moderate leverage and potential liquidity tightness. The net loss in Q2 2026 could pressure the balance sheet if the downturn persists.
IBM Technical Analysis
IBM is in a severe downtrend, with the stock price falling 25.3% over the past year and currently trading at $211.20, just 0.1% above its 52-week low of $211.03 and 36.5% below its 52-week high of $332.46. This positioning near the low end of the range suggests a deeply bearish sentiment and potential value trap, as the stock has lost over a third of its value from the peak. The 1-year price change of -25.3% contrasts sharply with the S&P 500's gain of 20.9%, indicating significant underperformance and a loss of investor confidence.
Short-term momentum is decisively negative and accelerating. Over the past month, IBM has dropped 21.4%, and over three months it has fallen 15.9%, with the 1-month decline steeper than the 3-month, signaling intensifying selling pressure. This divergence from the longer-term downtrend (1-year -25.3%) suggests a capitulation event, likely triggered by the July 14 profit warning, rather than a mere pullback. The relative strength versus the S&P 500 is deeply negative at -22.0% over 1 month and -46.2% over 1 year, confirming the stock is in a freefall relative to the market.
Key support is at the 52-week low of $211.03, which was tested on July 15; a breakdown below this level would open the door to further downside, potentially toward the $195 low analyst target. Resistance is at the 52-week high of $332.46, but more immediate resistance lies near the $250 area, where the stock traded in late June. With a beta of 0.675, IBM is less volatile than the market, meaning its 25% drop is even more striking—it reflects company-specific risk rather than broad market moves. The current price action suggests a high-risk environment with potential for further declines if support fails.
Beta
0.68
0.68x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$204-$332
Price range past year
Annual Return
-24.6%
Cumulative gain past year
| Period | IBM Return | S&P 500 |
|---|---|---|
| 1m | -18.9% | +0.3% |
| 3m | -16.1% | +4.7% |
| 6m | -30.4% | +7.5% |
| 1y | -24.6% | +18.4% |
| ytd | -27.0% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBM Fundamental Analysis
IBM's revenue trajectory shows modest growth but with significant volatility. In Q1 2026, revenue was $15.92 billion, up 9.5% from $14.54 billion in Q1 2025, but Q4 2025 revenue of $19.69 billion was down 1.5% from Q4 2024's $17.55 billion (though Q4 2024 was lower). The most recent quarter (Q2 2026) reported gross profit of $9.91 billion, but revenue data is missing; however, the profit warning suggests a sharp deceleration. Segment data shows Software ($7.05B) and Consulting ($5.27B) as the largest contributors, with Infrastructure Services at $3.33B. The growth narrative is challenged by the shift in enterprise spending from software to hardware, which directly impacts IBM's software-centric model.
Profitability is mixed. Net income in Q1 2026 was $1.22 billion (net margin 7.6%), down from $2.19 billion in Q2 2025 (net margin 12.9%), indicating margin compression. Gross margin has been relatively stable around 56-59% over the past year, but operating margin fell from 18.2% in Q2 2025 to 13.9% in Q1 2026. The Q2 2026 income statement shows a net loss of $1.22 billion (from cash flow data), a dramatic swing from profitability, driven by a $9.9 billion operating expense line. This suggests a significant impairment or restructuring charge, consistent with the profit warning.
Balance sheet and cash flow show mixed signals. IBM has a debt-to-equity ratio of 2.06, indicating moderate leverage, and a current ratio of 0.93, suggesting potential liquidity tightness. However, free cash flow (FCF) remains strong: TTM FCF is $14.58 billion, and Q1 2026 FCF was $4.78 billion, providing ample cash for dividends and debt service. The dividend yield is 2.27%, and the payout ratio is 59%, which is sustainable given FCF. ROE is high at 32.4%, but this is partly due to leverage. The company generated $2.60 billion in operating cash flow in Q2 2026, but capital expenditures were only $0.39 billion, indicating strong cash generation. However, the net loss in Q2 2026 raises concerns about earnings quality.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$14.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBM Overvalued?
Since IBM has positive net income (TTM net income is positive, though Q2 2026 showed a loss), the primary valuation metric is the P/E ratio. The trailing P/E is 26.07x, while the forward P/E is 15.87x, implying the market expects earnings to rebound sharply. This gap of 39% suggests that the current price already discounts a significant earnings recovery, which may be optimistic given the recent profit warning. The PEG ratio of 0.35 indicates that the stock is cheap relative to expected growth, but this relies on forward estimates that may be revised downward.
Compared to the Information Technology Services industry, IBM's trailing P/E of 26.07x is at a premium to the sector average (industry average not provided, but typically around 20-22x). The price-to-sales ratio of 4.09x is also above the industry average of ~2.5x, suggesting IBM trades at a premium. This premium may be justified by IBM's strong brand, recurring revenue from software and services, and high gross margins (59.5%), but the recent profit warning challenges this narrative. The EV/EBITDA of 19.07x is also elevated relative to historical levels.
Historically, IBM's trailing P/E has ranged from 11x to 55x over the past two years. The current 26.07x is near the middle of this range, but the forward P/E of 15.87x is near the lower end, reflecting the market's expectation of a recovery. Compared to its own history, the stock is not at extreme valuation levels, but the sharp drop in price has compressed multiples. The price-to-book ratio of 8.46x is above the 5-year average of ~6x, suggesting the stock is not cheap on a book value basis. Overall, the valuation appears reasonable if earnings recover, but risky if the profit warning signals a structural slowdown.
PE
26.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IBM's financial health is under pressure from a dramatic earnings swing. Q2 2026 net income fell to a loss of $1.22 billion from a $2.19 billion profit a year earlier, driven by a $9.9 billion operating expense line that likely includes restructuring charges. The debt-to-equity ratio of 2.06 is elevated, and the current ratio of 0.93 suggests potential difficulty meeting short-term obligations. While TTM free cash flow of $14.58 billion is strong, the net loss raises questions about earnings quality and sustainability. Margin compression is evident: operating margin fell from 18.2% in Q2 2025 to 13.9% in Q1 2026, and net margin dropped from 12.9% to 7.6% over the same period. If the profit warning signals a prolonged downturn, cash flow could deteriorate, threatening the dividend (2.27% yield, 59% payout ratio).
Market & Competitive Risks: IBM faces significant external threats. The stock's beta of 0.675 suggests lower market correlation, but its 25% drop amid a rising S&P 500 (+20.9% over 1 year) indicates company-specific risk. The shift in enterprise spending from software to hardware, as highlighted in recent news, directly impacts IBM's software-centric model and could benefit competitors like Micron and Sandisk. Valuation compression is a key risk: the trailing P/E of 26.07x is above the industry average, and if earnings continue to disappoint, the multiple could contract further. Regulatory and geopolitical risks are moderate, but the narrow S&P 500 earnings growth concentration in energy and technology could lead to sector rotation away from legacy tech names like IBM.
Worst-Case Scenario: The most damaging chain of events would be a prolonged enterprise spending shift away from software, causing IBM's revenue to decline further. If the Q2 2026 loss is not a one-time event and earnings fail to recover, analysts could slash forward estimates, leading to multiple compression. The stock could break below its 52-week low of $211.03 and test the analyst low target of $195.00, representing a potential 7.7% decline from the current price. In a severe recession scenario, historical max drawdown of 35.85% would imply a price of ~$135, though this is less likely given IBM's diversified business. Realistically, an investor could lose 7-15% from current levels if the bear case materializes.
FAQ
The primary risk is the profit warning and the shift in enterprise spending from software to hardware, which directly impacts IBM's core business. Financially, the debt-to-equity ratio of 2.06 and current ratio of 0.93 indicate moderate leverage and potential liquidity concerns. The Q2 2026 net loss of $1.22 billion raises questions about earnings stability. Market risk includes the stock's severe underperformance (down 25.3% over 1 year vs. S&P 500 +20.9%) and its proximity to the 52-week low, which could trigger further selling. Company-specific risks include execution risk in the restructuring and the pace of AI monetization. The most severe risk is a prolonged downturn that forces a dividend cut or additional debt, which could push the stock below $195.
The 12-month outlook is highly uncertain. The bull case (25% probability) sees a recovery to $280-$330, driven by a rebound in software spending and successful restructuring. The base case (45% probability) expects the stock to trade in a $210-$260 range as earnings stabilize. The bear case (30% probability) targets $180-$210 if the spending shift persists and revenue declines. The most likely scenario is the base case, where the stock remains near current levels with limited upside until earnings visibility improves. The average analyst target of $296.07 implies 40% upside, but this is contingent on a turnaround that has yet to materialize.
IBM presents a mixed valuation picture. On a forward basis, the P/E of 15.87x is below the industry average of ~20-22x and near the low end of its historical range, suggesting undervaluation. The PEG ratio of 0.35 also indicates the stock is cheap relative to expected growth. However, the trailing P/E of 26.07x is above the industry average, implying the market is paying a premium for past earnings that may not be sustainable. The price-to-sales ratio of 4.09x is also above the sector median of ~2.5x. Overall, IBM appears undervalued on forward estimates but overvalued on trailing metrics, reflecting the market's expectation of a sharp earnings recovery. If that recovery fails to materialize, the stock could be overvalued.
IBM is a high-risk, high-reward proposition. The stock offers a 40% upside to the average analyst target of $296.07, but this is contingent on a successful turnaround. The forward P/E of 15.87x is cheap, but the trailing P/E of 26.07x is a premium, and the recent profit warning raises doubts about earnings quality. For patient, risk-tolerant investors with a 12-24 month horizon, IBM could be a good buy if the spending shift reverses. However, for conservative investors seeking stability, the stock's 25% decline and near-52-week low make it a risky bet. The biggest downside risk is a break below $211, which could lead to a further 7-15% decline toward the $195 low target.
IBM is more suitable for long-term investment (12-24 months) given its current volatility and uncertainty. The stock's beta of 0.675 is below the market, but the recent 25% drop shows it can be highly volatile on company-specific news. The dividend yield of 2.27% provides some income for long-term holders, but the payout ratio of 59% is sustainable only if free cash flow remains strong. Short-term trading is risky due to the stock's proximity to its 52-week low and negative momentum. A concrete minimum holding period of 12 months is recommended to allow time for the restructuring to take effect and for earnings to stabilize. Investors should monitor quarterly earnings closely and be prepared to exit if the stock breaks below $195.
